We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The pharmaceutical industry's primary methods of pricing products -- through
intellectual property rights and diversity pricing, which allows firms to charge
higher prices to those with greater ability to pay -- are under attack, a free-market
think tank concludes in a new paper opposing drug importation proposals.